Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:
American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025) Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"
The abstract will be made available on INOVIO's website following the conference.
About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts Media: Jennie Willson, (267) 429-8567, communications@inovio.com Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for-cancer-research-immuno-oncology-aacr-io-conference-302372309.html
SOURCE INOVIO Pharmaceuticals, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a strong portfolio led by Tyvaso, its inhaled therapy for pulmonary hypertension, and a growing pipeline targeting pulmonary arterial hypertension (PAH). Its existing therapies are leading to stronger topline and earnings growth; the 17% year-over-year growth in Q1 2025 revenue and a 17% compounded annual growth rate (CAGR) over the last five years are evidence of that. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price target to $385 from $410, reflecting a recalibration of expectations ahead of a key clinical update. Verma pointed to the company's upcoming Phase III readout for idiopathic pulmonary fibrosis (IPF), expected in the third quarter, as a potential high-impact event that could meaningfully influence the stock. While binary in nature, the analyst believes the risk/reward remains attractive at current valuation levels. Verma also highlighted Tyvaso as a continued bright spot for the company. He expects the therapy to see seasonally strong performance in both Q2 and Q3, which should support near-term revenue momentum. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now. Following a recent investor meeting with Neurocrine Biosciences' senior leadership, Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on the stock on June 4, keeping his price target steady at $165. The discussion covered several key areas of interest to investors, including commercial performance and future catalysts. A scientist in a labcoat examining a vial of experimental biopharmaceuticals. Management pointed to continued momentum in Ingrezza, with expectations for quarter-over-quarter sales growth in Q2 and a stronger performance in the second half of 2025. They also addressed investor concerns about potential pricing pressure on TEVA's Austedo under the Inflation Reduction Act. While the IRA remains a point of uncertainty, the management is working toward equal access with TEVA. The team also highlighted a significant population of untreated patients, underscoring long-term growth potential for VMAT2 inhibitors. Neurocrine Biosciences Inc. (NASDAQ:NBIX) is a leading neuroscience-focused biopharmaceutical company that discovers and develops treatments for patients with underserved neurological, neuroendocrine, and neuropsychiatric disorders. While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 hours ago
- Yahoo
Why Clover Health (CLOV) Shares Are Trading Lower Today
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 4.8% in the afternoon session after a filing revealed that the company's CEO, Wai Conrad, sold a portion of his holdings. According to a regulatory filing on July 11, 2025, CEO Wai Conrad sold 15,203 shares of Class A Common Stock on July 8 for a total of approximately $49,561. The transactions were made at prices ranging from $3.25 to $3.27 per share. While the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a predetermined time, the news can still create unease among investors. Insider selling, even when planned, is often scrutinized by the market for any signals about a company's future prospects, contributing to negative pressure on the stock price. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Clover Health? Access our full analysis report here, it's free. Clover Health's shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Clover Health is down 7.2% since the beginning of the year, and at $2.91 per share, it is trading 39.7% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health's shares 5 years ago would now be looking at an investment worth $261.71. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
